The 2nd Cell Therapy Analytical Development Summit Europe is an unmissable event for Europe’s top biotech and pharma! As the cell therapy industry continues to rapidly grow and evolve, the opportunity to learn from and collaborate with leading experts in the field will ensure that potency, characterisation and multi-region access are no longer bottlenecks in the cell therapy drug development pipeline.

With FDA regulatory holds on release assays and potency forming a prevailing bottleneck in the cell therapy space, there has never been a more important time for the European cell therapy community to unite to implement gold standard analytical development, effectively communicate with the EMA and secure market approval.

Join analytical development, CMC and process development industry experts to advance multi-region access, achieve consistent and scalable assay development and drive analytical standards to bring safe, high-quality cell therapies to patients across the European territories.

Attend the only cell therapy-focused, industry-facing and European-specific summit to gain valuable insights on everything analytical development: from comparability testing to batch-to-batch variability, potency assays to regulatory considerations…and more! Gain control of your manufacturing processes, assay development and analytical strategy with key thought leaders from the likes of Takeda, Novo Nordisk, Cellectis and Gadeta.

Join us at the 2nd Cell Therapy Analytical Development Summit Europe to gain a competitive edge in this fast-paced industry.